The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1326
Colchicine and Other Drugs for Gout
The full article is available to subscribers Subscriber Login   
Revised 12/3/09: In the Uricosuric agents paragraph, the last two words in the last sentence ("and theophylline.") were deleted.

Until the recent introduction of febuxostat (Uloric),1 no new drugs had been marketed for treatment of gout in the past 40 years. Colchicine, which has been available for decades as an unapproved drug, has now been approved by the FDA (Colcrys) for treatment and prophylaxis of gout flares. It was approved earlier only in combination with probenecid (Colbenemid, and others). The goals of gout treatment are three-fold: treating acute disease, preventing flares and reducing uric acid stores.2

ACUTE GOUT — Nonsteroidal anti-inflammatory drugs (NSAIDs) – Acute exacerbations of gout can be treated successfully in most patients with an NSAID, which should be started immediately at the onset of symptoms and taken regularly (not as needed) until resolution of the flare. There is no convincing evidence that indomethacin (Indocin, and others), a ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Colchicine and Other Drugs for Gout
Article code: 1326a
 Electronic, downloadable article - $25